VXRT:OTCMKTS
Vaxart Inc
0,43 $
arrow_downward
-0,02%(-0,000075) 1 d.
9. okt., 16:00:00 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: VXRT…
Atvērt
0,44 $
Augsta
0,45 $
Zema
0,43 $
Tirgus kapitalizācija
106,59 milj.
Vid. apjoms
265,13 tūkst.
Apjoms
198,22 tūkst.
Cenas/peļņas attiecība
2,66
Augstākā 52 ned.
0,84 $
Zemākā 52 ned.
0,30 $
Peļņa uz vienu akciju
0,16 $
Beta
1,05
Apgrozībā esošās akcijas
242,84 milj.
Darbinieku skaits
65
Atvērt
0,44 $
Augsta
0,45 $
Zema
0,43 $
Tirgus kapitalizācija
106,59 milj.
Vid. apjoms
265,13 tūkst.
Apjoms
198,22 tūkst.
Cenas/peļņas attiecība
2,66
Augstākā 52 ned.
0,84 $
Zemākā 52 ned.
0,30 $
Peļņa uz vienu akciju
0,16 $
Beta
1,05
Apgrozībā esošās akcijas
242,84 milj.
Darbinieku skaits
65
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Simply Wall Street
·
pirms 5 minūtēm
SolarEdge Technologies (SEDG) Appoints Gokul Krishnan To Lead North America Growth
Simply Wall Street
·
pirms 5 minūtēm
Does Board AI Hire Change The Bull Case For Roper Technologies (ROP)?
Simply Wall Street
·
pirms 5 minūtēm
Lineage (LINE) Following Its BSF Extension And The Undervalued Narrative
Yahoo Finance
·
pirms 3 stundām
The Nasdaq-100 Has Gained 20% or More 3 Years Running. This Streak Rests on Far Stronger Earnings Than 1999's.
Profils
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Par “Vaxart Inc”
Ģenerāldirektors-
Darbinieki65
Dibināšanas datumsmarts 2004
Galvenais birojsSouth San Francisco, Kalifornija, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnevaxart.com